An observational study in Shoulder Pain, Shoulder Injuries and Shoulder Fractures, sponsored by Zimmer Biomet. Enrolling by invitation at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-30.
Sponsored by Zimmer Biomet · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Shoulder Pain with a site in United States — 21 open to participants now, 28 under way, none of them phase 3. Shoulder Pain · United States.
Among the 146 studies in Shoulder Pain with a site in United States, this one is the 5th largest by planned enrollment of the 24 observational ones that give a count, is one of 15 that started in 2019, is one of 24 observational ones, reaches primary completion later than 22 of the 27 other live ones, and was the 92nd registered.
738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.
Browse Shoulder Pain studies →21 of the 146 studies in Shoulder Pain with a site in United States are open now. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18–45 · Healthy volunteers
Cedars-Sinai Medical Center · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Prisma Health-Upstate · Sites in United States
Ages 21–65 · Women only
Lisa Griffin · Sites in United States
Ages 60+
University of Florida · Sites in United States
Ages 18–50
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 10 · Phase 4 21
First in 2003; this study’s year is marked. 15 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 146 is above the median of 84 across 135 observational studies indexed under Shoulder Pain.
Median enrollment 50 across the 122 interventional studies, 65 across the 24 observational. Of the 101 that completed or were terminated, 32 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 146 have an industry lead sponsor. The 10 most frequent:
Zimmer Biomet is the lead sponsor of 275 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 19 (86%) have results posted.
Zimmer Biomet has 9 studies filed under Shoulder Pain — fewer than ten, so there is no comparison to draw.
12 of the studies in Shoulder Pain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07851233Rothman Institute OrthopaedicsPatient Education and Sling Use After Shoulder Surgery | 2026-11-30 |
| NCT06039345University of UtahShoulder RFA Pilot Study | 2026-12 |
| NCT07101250Prisma Health-UpstatePreoperative Acetazolamide | 2026-12-01 |
| NCT03653455Rush University Medical CenterPatient Outcomes Collection: How Can we do Better? | 2026-12-31 |
| NCT07400146Cedars-Sinai Medical CenterBupivacaine With Epinephrine Over Diaphragm in Laparoscopy | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 146 studies in Shoulder Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this retrospective/prospective enrollment and prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance and clinical benefits of the Comprehensive Primary Micro Stem and Comprehensive Anatomic Versa-Dial Titanium Humeral Heads when used for primary and revision total shoulder arthroplasty (implants and instrumentation) at 1,3,5,7 and 10 years*. Comprehensive Primary Micro Stem and Comprehensive Anatomic Versa-Dial Titanium Humeral Heads have been on the market since 2007, but have insufficient data to support 10 years of clinical history. Therefore, a prospective aspect to the study will be utilized in order to collect long-term data.
The objective of this retrospective/prospective enrollment and prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance and clinical benefits of the Comprehensive Primary Micro Stem and Comprehensive Anatomic Versa-Dial Titanium Humeral Heads when used for primary and revision total shoulder arthroplasty (implants and instrumentation) at 1,2,3,5,7 and 10 years*. Comprehensive Primary Micro Stem and Comprehensive Anatomic Versa-Dial Titanium Humeral Heads have been on the market since 2007, but have insufficient data to support 10 years of clinical history. Therefore, a prospective aspect to the study will be utilized in order to collect long-term data.
The primary objective of this study is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications, and adverse events. Relation of the events to either implant or instrumentation should be specified.
The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs).
*The most recent available data will be used. If any of the listed time points are not available, data will be used from last available time point and follow-up will move forward at the closest available time point.
A consecutive series of subjects implanted with the Comprehensive Primary Micro Stem and/or the Comprehensive Anatomic Versa-Dial Titanium Humeral Heads in primary and/or revision total shoulder arthroplasty according to the approved indications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient must have undergone a primary or revision shoulder arthroplasty with the Comprehensive Micro Stem and/or the Comprehensive Anatomic Versa-Dial Humeral Heads for a cleared indication. Cleared indications include the following:
Exclusion Criteria:
Relative contraindications include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.
Device: Comprehensive Primary Micro Stem
Patients that have been implanted with the Comprehensive Anatomic Versa-Dial Titanium Humeral Heads to repair shoulder malfunction/disease.
Device: Comprehensive Anatomic Versa-Dial Titanium Humeral Head
Patients that have been implanted with the Comprehensive Primary Micro Stem to repair shoulder malfunction/disease.
Patients that have been implanted with the Comprehensive Anatomic Versa-Dial Titanium Humeral head to repair shoulder malfunction/disease.
Device Safety assessed through the frequency and incidence of revisions, complications and Adverse Events
The primary objective of this study is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications, and adverse events. Relation of the events to either implant or instrumentation should be specified.
Time frame: Out to 10 years
Device Performance and Benefits evaluated through the Oxford Shoulder Score outcome measure.
The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs), through the use of the Oxford Shoulder Score (OSS). The OSS is a 12 item questionnaire, each with 5 potential answers. Patients rate their symptoms from 1 (minimal symptoms) to 5 (severe symptoms). The combined total gives a minimum score of 12 and a maximum of 60. Higher scores in the OSS imply worse functionality.
Time frame: Out to 10 years
Device Performance and Benefits evaluated through the Patient Assessment Questionnaire.
The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs), through the use of the Patient Assessment Questionnaire where adverse events and/or complications (yes or no), patient's activity level with regard to operative side, based on the UCLA Activity Score(wholly inactive 10, mostly inactive 9, sometimes participates in mild activities 8, regularly participates in mild activities 7, sometimes participates in moderate activities 6, regularly participates in moderate activities 5, regularly participates in active events 4, regularly participates in very active events 3, sometimes participates in impact sports 2, regularly participates in impact sports 1, or not recorded), and the Reported Score if Individual Scores are not available of the Oxford Shoulder Score. The UCLA Activity score rating is from 10 being the best outcome score, and 1 being the worst.
Time frame: Out to 10 years
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2019 (actual). Primary completion is estimated for Jul 2028, 103 months after the start.
Of 54 observational studies under Shoulder Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 35. This study's planned 103 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.